GEXVal Inc. Announces Collaboration with FRAXA-DVI
2023/2/28
GEXVal Inc.February 28, 2023 GEXVal Inc. is pleased to announce that we have initiated a collaboration project […]
Phase 1 Study of GXV-001 in Australia: Start of Repeated-Dose Study
2023/2/15
GEXVal Inc.February 15, 2023 GEXVal Inc., through its wholly-owned subsidiary GEXVal AU Pty Ltd., is conductin […]
Initiation of Basic Research for Drug Repurposing Utilizing Fugaku
2023/1/20
GEXVal Inc.January 20, 2023 GEXVal Inc. (hereinafter "GEXVal") has started research on AI (Artificial Intellig […]
Successfully Completed Phase I Single Dose Study for GXV-001
2023/1/10
GEXVal Inc.January 10, 2023 GEXVal Inc. is conducting a Phase I study for GXV-001, a new drug candidate, throu […]
GEXVal Gave Presentation at KIRIN
2022/12/27
GEXVal Inc.December 27, 2022 Juran Kato, PhD, president and CEO of GEXVal ., was invited by Kirin Holdings Com […]